Global Medical Device Podcast powered by Greenlight Guru

In this episode, Etienne Nichols sits down with Staci Miller, a Human Factors and UX Strategist at GenUX, to demystify the role of human factors (HF) in the medical device regulatory pathway. Staci explains that many companies mistakenly treat HF as a "box-checking" exercise late in development, leading to costly submission delays or rejections when the FDA finds the documentation fails to tell a cohesive safety story.The conversation dives deep into the technical distinctions between a Use-Related Risk Analysis (URRA) and a User Failure Mode and Effects Analysis (uFMEA). Staci provides a framework for deciding which approach fits your product, emphasizing that while large conglomerates with post-market data may lean toward uFMEAs, startups and those with novel devices should prioritize the URRA to effectively map out user interactions without the crutch of existing market data.Finally, Staci addresses one of the most persistent myths in the industry: the idea that clinical trial data can replace human factors validation. She clarifies that while the two can overlap in specific, premeditated circumstances (such as complex implants like aortic valves), they serve entirely different masters—one focused on clinical efficacy and the other on the safety of the user interface across diverse environments.Key Timestamps04:12 – The common disconnect: Integrating Human Factors into ISO 14971 risk management.06:45 – URRA vs. uFMEA: How to choose based on your post-market data and predicate device status.10:30 – The "Definition of Done": Tracking the lifecycle of HF documentation from phase zero to market release.13:15 – System errors vs. Use errors: How to identify root causes during summative studies.18:50 – The "Clinical Trial Myth": Why efficacy data is not the same as usability validation.22:10 – Design Inputs vs. Design Outputs: The "Blueprint and the House" analogy for FDA submissions.25:40 – The impact of the "Use Environment": Testing for movement in ambulances and lighting in radiology suites.Quotes"The FDA doesn't put things out there just to have a good time... If they've made human factors a requirement and you're treating it as a 'suggestion,' you're giving yourself enough rope to hang yourself." - Staci Miller"People are obsessed with the product themselves—the design outputs. But the FDA wants to see the design inputs. They want to see the blueprints of how you built that house, not just the wallpaper." - Staci MillerTakeawaysPremeditation is Key: If you intend to use clinical trial data for HF validation, it must be planned in the protocol from the start; you cannot retroactively claim clinical data satisfies usability requirements.Map User Groups Early: Distinguish clearly between primary and secondary users. Bloating user sets without explaining how or why they engage with the device complicates your risk profile.Environment Matters: Documentation must account for the physical "10,000-foot view," including noise, lighting, and motion (e.g., an ambulance), as these are often where critical use errors occur.HF is Risk Management: Human factors should not live in a silo. It must align with the scales of harm (negligible to catastrophic) defined in ISO 14971 and work in tandem with Quality and Regulatory teams.ReferencesISO 14971: The global standard for the application of risk management to medical devices.FDA Human Factors Guidance: The primary document outlining expectations for usability testing and documentation.Etienne Nichols: LinkedIn ProfileMedTech 101: URRA vs. uFMEAThink of a uFMEA (User Failure Mode and Effects Analysis) like a car manufacturer looking at an old model to see why the brakes failed in the past—it relies on known data to fix specific parts.A URRA (Use-Related Risk Analysis) is like teaching someone to drive a brand-new type of vehicle (like a spaceship) for the first time. Since you don't have "crash data" yet, you have to carefully map out every single step the pilot takes and imagine every possible way they could push the wrong button in the heat of the moment.SponsorsGreenlight Guru: This episode is brought to you by Greenlight Guru, the only quality management platform designed specifically for the medical device industry. Whether you need to manage your QMS to stay compliant with ISO 14971 or streamline your clinical data through their EDC solutions, Greenlight Guru helps you move faster with less risk.Feedback Call-to-ActionWe want to hear from you! Do you have questions about your specific regulatory pathway or a topic you’d like us to cover? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, or suggestions to podcast@greenlight.guru.

In this episode, Etienne Nichols sits down with regulatory expert Mike Drues, President of Vascular Sciences, to discuss the "culture shock" international medical device companies face when entering the U.S. market. They challenge the traditional assumption that a device should always launch outside the U.S. first, noting that shifting regulatory landscapes—especially in Europe—have made the U.S. a more attractive primary entry point for many.The conversation pivots to the technical and strategic nuances of "same device, different claims." Mike explains that if a device maintains the same design but utilizes different labeling or indications for use across borders, it is technically a different device in the eyes of regulators. This creates significant complexity for Quality Management Systems and post-market surveillance, particularly concerning reporting requirements for Class III (PMA) devices.Finally, the duo explores the "trap of equivalency," where companies mistakenly assume that a CE Mark or other international approval guarantees a smooth path through the FDA. From differing consensus standards to the strategic use of OUS (Outside US) clinical data, the episode provides a roadmap for global players to synchronize their regulatory and reimbursement strategies early in the development lifecycle.Key Timestamps01:45 - Challenging the assumption: Should you always launch outside the US first?04:12 - Defining the "International Company": Why every developer should think globally from day one.05:30 - The Labeling Trap: Why the same hardware with different claims is a different device.07:50 - Post-market surveillance nuances: Reporting OUS issues in a US PMA submission.11:15 - The "Sniff Test": Does a CE Mark actually help you with the FDA?12:40 - Leveraging Real-World Evidence (RWE) from international markets for US submissions.14:30 - The "Species Expansion" concept: Applying regulatory logic across different use cases.16:15 - Consensus Standards: Why the FDA might not recognize the "most current" version of a standard.20:00 - International Regulatory Strategy: Calculating the "lowest common denominator" for multi-country launches.25:20 - Using 100% OUS clinical data for FDA submissions: The three essential caveats.Quotes"If you’re marketing the same device—same design, same materials—but the labeling and claims are different in the EU versus the US, then technically, it is not the same device." - Mike Drues"The regulatory logic is agnostic of the scenario. Whether it's a label expansion or a 'species expansion' from a dog to a human, the underlying logic remains the same." - Mike DruesTakeawaysSync Your Standards: Do not assume the FDA recognizes the same version of a standard (e.g., ISO 10993-1) as international bodies. Always verify via the CDRH Recognized Consensus Standards database.Design for the "Lowest Common Denominator": Identify your top 3–5 target markets early and pool their requirements to avoid redundant benchtop or clinical testing.Rethink Clinical Trials: While the FDA prefers domestic data, OUS data can be used if you can prove the patient population and user profiles (physicians/nurses) are representative of the US demographic.Anticipate "Off-Label" Pressure: If you market a device in Canada with claims not yet approved in the US, be prepared for US clinicians to find that information online and ask for "anticipated off-label use."ReferencesFDA Recognized Consensus Standards Database: Essential tool for verifying which versions of international standards the FDA currently accepts.Greenlight Guru QMS & EDC: Solutions for managing complex, multi-region quality systems and clinical data.Etienne Nichols’ LinkedIn: Connect with the host for more MedTech insights.MedTech 101: Label ExpansionThink of Label Expansion like a smartphone software update. The hardware (the phone) stays the same, but the update allows the phone to do something it couldn't do before—like a new photography mode. In MedTech, if you have a stent approved for use in the leg (the "old label") and you want to use that same stent in the heart, you apply for a "label expansion." You aren't changing the device; you're just proving it’s safe and effective for a new job.Sponsors: Greenlight GuruThis episode is brought to you by Greenlight Guru. Navigating international waters requires a robust foundation. Greenlight Guru’s Quality Management Software (QMS) helps you maintain a "single source of truth" for your design history files and labeling, while their Electronic Data Capture (EDC) solution streamlines the collection of the clinical data you'll need to satisfy both the FDA and international regulators. Whether you are managing post-market surveillance for a PMA or running a multi-center global trial, Greenlight Guru has you covered.Feedback Call-to-ActionWe want to hear from you! Did this episode change your mind about your international launch strategy? Do you have a "culture shock" story from bringing a device to the US? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our listeners.

This episode features Ivanny Franklin, Managing Partner at MedSight Capital, who brings a wealth of experience from her background in molecular biology and her decade-long tenure at NAMSA. The conversation centers on the shifting paradigms of medical device investment, specifically how the industry is moving away from service-based models toward a focus on clinical outcomes.Etienne and Ivanny explore the critical intersection of global regulatory bodies—such as the NMPA in China and the FDA in the US—and the necessity of a cohesive clinical evidence strategy. Ivanny emphasizes that for startups, understanding market-specific data requirements is not just a regulatory hurdle but a fundamental component of commercialization and investor conviction.The discussion also dives into the "patient empowerment" movement, fueled by the convergence of wearables, AI, and at-home monitoring. Ivanny shares her bullish outlook on technologies that give patients control over their data, while acknowledging the tension this creates for physicians and the ongoing need for rigorous regulatory oversight to ensure safety and effectiveness.Key Timestamps[03:15] Global Regulatory Strategy: Insights into the NMPA (formerly CFDA) and why China requires in-country clinical evidence.[07:42] Leveraging Data: How to run a single clinical trial to satisfy multiple global regulatory bodies.[10:18] The At-Home Monitoring Shift: The rise of wearables and OTC testing in the wake of COVID-19.[13:45] The "Data Gap": Addressing the friction between patient-gathered data and physician adoption.[18:22] Investment Non-Negotiables: Why revenue-generating companies and clear regulatory classifications are key for MedSight Capital.[23:10] Diligence and Deception: The importance of honesty regarding reimbursement codes and 510(k) vs. PMA paths.[27:45] SPV vs. Hedge Fund Models: A breakdown of how Special Purpose Vehicles allow family offices to be nimble in MedTech.Quotes"FDA and NMPA, for example, are quite strict in clinical evidence coming from in-country... as a startup, you really need to understand can we run a single trial with multiple global sites to achieve clearance cohesively." - Ivanny Franklin"I’m an advocate for [at-home monitoring]. I do think that’s the future. However, there is concern around what types of information should patients be receiving and how are they going to act on that information?" - Ivanny FranklinTakeawaysRegulatory is the Roadmap: An investment is often "de-risked" based on the clarity of the regulatory path. If a founder cannot distinguish between a 510(k) and a PMA, it is a major red flag for investors.Harmonize Your Trials: To achieve "economies of scale" in clinical evidence, work with consultants to design trials that meet the stringent requirements of both the FDA and international bodies like the NMPA early on.Commercial Scalability over Hype: For revenue-generating companies, investors are less concerned with the "idea" and more focused on physician retention, training, and the cost of scaling the sales team.Honesty in Reimbursement: Never "make up" or guess CPT codes. Investors utilize experts (like ex-FDA personnel) to pressure-test your reimbursement strategy during diligence.ReferencesNMPA (National Medical Products Administration): The primary regulatory body for China (formerly the CFDA).NAMSA: A world-leading Medical Device CRO mentioned as Ivanny’s former professional home.LSI (Life Science Intelligence): The upcoming conference mentioned where Etienne and Ivanny will speak on a panel.Greenlight Guru: The preferred platform for QMS & EDC solutions to manage medical device quality and clinical data.Etienne Nichols: Connect on LinkedIn.MedTech 101: SPV (Special Purpose Vehicle)Think of a Special Purpose Vehicle (SPV) like a "carpool" for investors. Instead of a massive bus (a Hedge Fund) that picks up everyone's money and decides where to go over several years, an SPV is a single car created for one specific trip—in this case, one specific company.Investors put their money into the SPV, and the SPV makes one investment in one startup. This allows smaller investors or family offices to pool their resources together to act as one large "passenger" on a company's cap table.SponsorsThis episode is brought to you by Greenlight Guru. Moving from a "service-based" model to an "outcome-based" model requires impeccable data and quality management. Greenlight Guru offers both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions designed specifically for the medical device industry. Whether you are gathering clinical evidence for an NMPA submission or scaling a revenue-generating product, Greenlight Guru helps you stay compliant and efficient.Feedback Call-to-ActionWe want to hear from you! Did this breakdown of investment vehicles help you? Do you have suggestions for future MedTech topics? We provide personalized responses to every listener who reaches out. Send your thoughts, reviews, and questions to podcast@greenlight.guru.

In this episode, Etienne Nichols sits down with Edwin Lindsay, a seasoned MedTech operator and QARA leader, to discuss the systemic challenges facing the pediatric medical device market. Following a personal experience in a neonatal ward, Edwin highlights the stark reality that many pediatric treatments rely on adult devices adapted off-label, often leading to safety risks and clinical inefficiencies.The conversation delves into the "mismatch" of the pediatric market: these devices require the same rigorous regulatory and quality standards as adult products but offer significantly lower financial upside due to smaller patient populations. This creates a barrier for investors and manufacturers, leaving clinicians and nurses to "work miracles" with tools that aren't always fit for purpose.Despite these hurdles, Edwin shares an optimistic vision for the future. He discusses his initiative to build a collaborative network of experts—including regulatory consultants, testing houses, and grant writers—willing to provide pro-bono or at-cost support for pediatric startups. The goal is to create a streamlined regulatory roadmap that prioritizes patient safety without the prohibitive costs that currently stall innovation.Key Timestamps00:45 – The "Pediatric Gap": Why pediatric devices have adult-level requirements but lower ROI.03:12 – Personal Insight: Edwin’s experience in the hospital and the "Guinness philosophy" of giving back.05:30 – The danger of adhesives and adapting adult materials for newborn skin.08:15 – Building a pediatric volunteer network: Testing houses and consultancies stepping up.11:40 – Regulatory Roadmaps: Navigating the age variability from premature infants to adolescents.14:50 – Off-label usage risks and the "mindset shift" required for manufacturers.18:25 – Micro-timestamp: The FDA’s Humanitarian Device Exemption (HDE) and P-Sub programs.21:10 – Real-world clinical friction: Alarm fatigue and sensor sensitivity in NICU settings.25:40 – The hidden costs: Manufacturing complexity, multiple SKUs, and low-volume production.Quotes"We need to give clinicians the correct tools to work their miracles. They don't want to use products off-label; they want devices actually designed for the children they are saving." - Edwin Lindsay"If you have a pediatric project, there is a community behind you. We are breaking down the barriers of risk and cost because these babies deserve a chance." - Edwin LindsayTakeawaysRegulatory Flexibility: Utilize specific FDA pathways like the Humanitarian Device Exemption (HDE) and the Pediatric Submissions (P-Sub) program to gain early feedback and specialized guidance.Collaborative Cost-Sharing: Seek out "altruistic" partners; many testing houses and manufacturers are willing to work at-cost or under different financial models for pediatric-specific innovations.Design for Sensitivity: Pediatric innovation isn't just about miniaturizing adult tech—it requires solving unique issues like alarm fatigue and skin sensitivity (e.g., non-damaging adhesives).Workflow Integration: Engage the "head nurse" early in R&D to ensure the device fits into the high-stress environment of a pediatric ward without adding to clinical fatigue.ReferencesFDA HDE Program: A regulatory pathway for devices intended for diseases or conditions that affect small populations.Greenlight Guru: The industry-leading platform for QMS & EDC solutions, helping MedTech companies maintain compliance while accelerating pediatric product development.Etienne Nichols on LinkedIn: Connect with Etienne for more MedTech insights.MedTech 101: Off-Label UseIn the medical device world, "Off-Label" means using a device for a purpose, or on a patient population (like infants), that the FDA has not officially cleared.Think of it like this: Imagine you have a high-tech hiking boot designed for a grown man, but you have to put it on a toddler because no one makes toddler-sized hiking boots. You might be able to make it stay on with extra socks and tape, but it won't support the child’s foot correctly and might cause them to trip. In pediatrics, doctors often have to "tape the boot" because specialized devices simply don't exist.Feedback Call-to-ActionWe want to hear from you! Are you working on a pediatric breakthrough, or have you faced challenges in this niche market? Whether you have a topic suggestion or a question for Edwin, send us an email at podcast@greenlight.guru. We read every message and pride ourselves on providing personalized responses to our community.SponsorsThis episode is brought to you by Greenlight Guru. Navigating the complex regulatory landscape of pediatric devices requires a robust foundation. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions are specifically designed to help MedTech innovators manage risk and clinical data with precision. Whether you are a one-person startup or a global entity, Greenlight Guru helps you get safe, effective technology to patients faster.

In this episode, Etienne Nichols sits down with Dr. Kristy Katzenmeyer-Pleuss, President and Founder of KP Medical Device Consulting, to unpack the complexities of the medical device life cycle. The conversation centers on how manufacturers often overlook critical phases of a product’s journey, such as transportation, shelf life, and the decommissioning phase, focusing instead solely on the point of patient use.Dr. Katzenmeyer-Pleuss highlights the significance of the upcoming ISO 10993-1:2025 standard and its renewed emphasis on life cycle-based risk assessments. She explains how the transition between global markets—particularly between the EU and the US—can lead to unexpected FDA deficiencies when manufacturers rely on justifications that worked for notified bodies but do not meet more stringent FDA testing expectations for reusable or in situ curing devices.The discussion concludes with actionable advice on early design decisions, such as narrowing down material suppliers and reprocessing options to reduce testing burdens. They also explore the critical need for cross-functional communication and quality system integration to ensure that learnings from one project or regulatory interaction are captured and applied across a company’s entire portfolio.Key Timestamps01:45 – Introduction of Dr. Kristy Katzenmeyer-Pleuss and the mission of KP Medical Device Consulting.04:12 – Defining the Medical Device Life Cycle: Concept to decommissioning and the "hidden" phases in between.05:30 – ISO 10993-1:2025: The impact of the new biological evaluation standard on risk-based approaches.09:15 – Global Regulatory Discrepancies: Why a device approved in Europe might face hurdles at the FDA regarding "worst-case" testing.13:40 – Reusable Devices & Reprocessing: Managing the "permutation explosion" of cleaning agents and sterilization cycles.17:22 – Early Design Decisions: How limiting options in the IFU can significantly decrease your regulatory testing burden.21:05 – In Situ Curing Devices: The unique testing challenges of materials that change states during use.25:10 – Quality System Integration: Strategies for linking regulatory deficiencies and materials across multiple projects.Quotes"The life cycle is really the concept of the medical device from when it’s a concept all the way through to the end where you are disposing or decommissioning... shelf life and transport are steps that usually don’t get a lot of focus, but they are very important." - Dr. Katzenmeyer-Pleuss"You might have one device where literally they don’t ask these questions at all, and then other times they’re very, very picky... the longer you go in that process, the harder it is to pivot without spending a lot of time and money." - Dr. Katzenmeyer-PleussTakeawaysFront-load Risk Assessments: Don’t wait for FDA deficiencies to consider how shelf life or reprocessing affects device safety; integrate these into the biological evaluation plan from day one.The "Worst-Case" Strategy: When designing testing protocols for reusable devices, aim for a "worst-case" scenario that covers future iterations or additional suppliers to avoid redundant, expensive re-testing.Standardize Your IFU Early: Providing users with infinite cleaning or sterilization options creates an exponential increase in testing requirements; narrow these down to the essentials to streamline market entry.Break the Silos: Use your QMS to link specific material risks or regulatory feedback across different project teams so that knowledge isn't lost when personnel leave.ReferencesISO 10993-1:2025: The updated international standard for the biological evaluation of medical devices within a risk management process.Etienne Nichols on LinkedIn: Connect with the host for more MedTech insights.MedTech 101: In Situ CuringIn this episode, Dr. Katzenmeyer-Pleuss mentions In Situ Curing. Think of this like a medical-grade "liquid bandage" or dental filling. The device starts as a liquid or gel and is applied to the body, where it then hardens into a solid "in the spot" (in situ).From a regulatory standpoint, this is complex because you aren't just testing one device; you have to test the safety of the liquid, the safety of the solid, and any chemicals released during the hardening process. It is essentially three devices in one when it comes to testing.SponsorsThis episode is brought to you by Greenlight Guru. When navigating the complex life cycle of a medical device—from the initial risk assessments discussed today to post-market surveillance—you need a unified system. Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions work together to ensure your data is linked, your testing is documented, and your clinical trials are seamless. By connecting your quality and clinical data, you can avoid the "disjointed" project management pitfalls Etienne and Kristy discussed.Feedback Call-to-ActionWhat are your biggest hurdles in managing the full medical device life cycle? We want to hear from you. Whether it's a specific regulatory challenge or a topic suggestion for a future guest, send your thoughts to podcast@greenlight.guru. We read every email and pride ourselves on giving personalized responses to our MedTech community.

In this episode, Etienne Nichols sits down with Thor Rollins, a leader at Nelson Labs and the convener of the committee revising ISO 10993-1. The conversation centers on the newest 2025 version of the standard, which represents a massive philosophical shift from a "checkbox" testing mentality to a rigorous, risk-based approach aligned with ISO 14971.Rollins explains that modern medical devices are far more complex than the metal and hard plastics of the past. With the rise of degradable materials, coatings, and nanomaterials, traditional animal testing often fails to provide the best science. The new standard introduces critical concepts such as biological risk estimation, foreseeable misuse, and a comprehensive lifecycle evaluation that looks beyond "time zero" safety.The duo also discusses the practical implications for manufacturers, including the controversial requirement to evaluate biocompatibility at the end of a product's lifecycle—a particular challenge for reprocessed devices. Rollins provides insider knowledge on the US’s stance on the revision, the timeline for FDA recognition, and how companies can leverage biological equivalence to potentially reduce their testing burden.Key Timestamps01:45 – The shift from "checkboxing" to a risk-based approach.03:10 – The rapid timeline of the 2025 revision and the influence of ISO 14971.04:22 – Lifecycle Evaluation: Assessing safety beyond the "brand new" state.06:50 – Chronic toxicity vs. acute reactions: Why front-end evaluation matters.08:15 – Foreseeable Misuse: When doctors use scopes outside their intended anatomy.12:10 – The concept of Bioequivalence: Using existing data to justify reduced testing.13:45 – Breakthrough: The removal of material-mediated pyrogenicity testing for known materials.15:30 – Why the US voted "No" on the current draft: A call for better guidance.18:50 – Notified Bodies and MDR: The 2025 version as "State of the Art."21:15 – Practical chemistry tests for aging polymers (DSC, GPC, FTIR).25:40 – Advice for small vs. large companies on building material databases.Quotes"The testing that we developed back in the 50s and 60s actually doesn't really work the best with some of these complex devices... we've been moving the standard away from what we call checkboxing." - Thor Rollins"I only say that expensive tests always impact innovation. We don't want to over-test, but we want to do the right tests." - Thor RollinsTakeawaysLifecycle is the New Frontier: You must now evaluate biocompatibility throughout the product's life, especially for reprocessed devices that may degrade after hundreds of cleaning cycles.Foreseeable Misuse is a Regulatory Reality: If it is likely a clinician will use your device off-label (e.g., a pulmonary scope used in vascular applications), you must account for that biological risk in your assessment.Leverage Bioequivalence: Stop testing the same stainless steel or titanium repeatedly. Use existing data and internal databases to justify "no testing" for known materials and processes.Partner with Expertise: Because the standard is less prescriptive and more risk-based, the quality of your Biological Evaluation Plan (BEP) depends entirely on the expertise of the person writing it.Chemistry over Animals: Whenever possible, use chemistry (Extractables & Leachables) and in vitro methods to replace legacy animal tests, as the 2025 revision officially begins to phase out certain animal-based requirements.ReferencesISO 10993-1:2025: The primary global standard for the biological evaluation of medical devices.ISO 14971: The standard for the application of risk management to medical devices, now heavily integrated into 10993-1.Nelson Labs: The laboratory where Thor Rollins leads biocompatibility strategy.Etienne Nichols: Connect with Etienne on LinkedIn.MedTech 101: BioequivalenceThink of bioequivalence like buying a generic medication versus a brand-name one. If you know the ingredients (materials) and the way they are manufactured (processes) are identical to a device that has already been proven safe on the market, you shouldn't have to re-run expensive, time-consuming tests. In MedTech, this means showing that your "New Device B" is biologically the same as your "Proven Device A" because they use the same grade of titanium and the same sterilization method.SponsorsThis episode is brought to you by Greenlight Guru. As the industry shifts toward a risk-based approach as seen in ISO 10993-1:2025, having a centralized source of truth is vital. Greenlight Guru's QMS (Quality Management System) allows you to integrate risk management directly into your design process, while their EDC (Electronic Data Capture) solution helps you gather the clinical evidence needed to prove long-term safety. When your risk assessments and clinical data live in the same ecosystem, "state of the art" compliance becomes a standard, not a struggle.Feedback Call-to-ActionWe want to hear from you! How is your team preparing for the 2025 revision of ISO 10993-1? Are you concerned about the lifecycle evaluation requirements? Send your thoughts, questions, or topic suggestions to podcast@greenlight.guru. We read every email and love providing personalized responses to our community.

This episode explores the transition from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR) and the foundational elements required for medical device compliance. Host Etienne Nichols and guest Mike Drues discuss the philosophy of building a usable system rather than a "museum of SOPs," emphasizing that the standard list of QMS sections should be viewed as a starting point rather than an exhaustive checklist.The conversation examines the critical differences between 510(k), De Novo, and PMA pathways regarding manufacturing requirements. While a 510(k) submission may not strictly require detailed manufacturing information at the time of filing, Mike explains why companies must remain audit-ready from the moment they register their establishment with the FDA. The discussion clarifies the timing of registration and the "radar" companies enter once they become commercially active.Finally, the dialogue focuses on a "triage" approach for resource-constrained startups. By prioritizing Design Controls and Risk Management during early development, teams can remain compliant and ethical without over-investing in post-market systems, such as complaint handling, before they have a product on the market. Mike warns against the dangers of "copy-and-paste" quality systems, urging manufacturers to use professional judgment to tailor their processes to their specific technology.Key Timestamps00:00 - Introduction to QMS requirements and guest Mike Drues.03:45 - The core sections of a QMS according to the Quality System Regulation.05:12 - Why the QSR list is a starting point, not a stopping point.08:20 - Regulatory vs. Ethical vs. Economical: The three legs of the medical device stool.10:30 - Do you need a full QMS for 510(k) vs. PMA submissions?13:15 - Understanding the timing and strategy for FDA Establishment Registration.15:40 - The Triage Approach: Which QMS sections matter most during early development?19:00 - The dangers of boilerplate SOPs and non-specific quality manuals.Quotes"This is a starting point. This is not a stopping point... Use your own good judgment." — Mike Drues"The goal is not really to build a museum of SOPs; the goal is a quality management system that teams will actually use." — Etienne NicholsTakeawaysPrioritize the Big Four: During the development phase, focus your limited resources on Design Controls, Risk Management, Document Control, and Supplier Quality Management.Understand Pathway Nuances: While 510(k) submissions don't require manufacturing details, you must be fully compliant and ready for inspection once your establishment is registered and the product is launched.Avoid Boilerplate SOPs: Quality systems must be specific to your organization. Including irrelevant device types or procedures in your QMS is a significant red flag for FDA inspectors.Strategic Registration: Register your establishment 60–90 days before your planned commercial launch to manage costs and stay off the FDA inspection radar until necessary.The Preamble is Key: Read the preamble of the QSR to understand the "why" behind the regulations, which allows for better justification of your quality decisions during an audit.ReferencesFDA Design Control Guidance (1997): A foundational document for medical device engineering and documentation.FDA Establishment Registration: Guidance on the timing and requirements for small business fee waivers.Etienne Nichols LinkedIn: https://www.linkedin.com/in/etiennenichols/MedTech 101 SectionConcept: The Quality Management System (QMS) Think of a QMS like a pilot’s pre-flight checklist. You don't just "wing it" when you get into a cockpit; you have a documented process to ensure the engine is working, the fuel is full, and the wings are clear. For a small plane (a low-risk Class I device), your checklist is shorter and simpler. For a commercial jumbo jet (a high-risk Class III device), the checklist is massive and detailed. However, the goal for both is identical: ensuring the passengers (the patients) arrive safely at their destination through a repeatable, controlled process.SponsorsThis episode is brought to you by Greenlight Guru. The subject of right-sizing your quality system is exactly why Greenlight Guru offers both QMS and EDC solutions. Their Ultralight eQMS is designed specifically for fast-moving, product-led teams who need a flexible, compliant system without the overhead of a "museum of SOPs." Whether you are in early-stage R&D or preparing for a global launch, Greenlight Guru provides the tools to keep your quality and clinical data connected and audit-ready.Feedback Call-to-ActionWe want to hear from you! What are the biggest hurdles your team faces when scaling your quality system? Send your feedback, reviews, and topic suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our listeners.

In this episode, host Etienne Nichols sits down with Ashkon Rasooli, founder of Ingenious Solutions and a specialist in Software as a Medical Device (SaMD). The conversation previews their upcoming session at MD&M West, focusing on the critical intersection of generative AI (GenAI) and quality assurance. While many AI applications exist in MedTech, GenAI presents unique challenges because it creates new data—text, code, or images—rather than simply classifying existing information.Ashkon breaks down the specific failure modes unique to generative models, most notably "hallucinations." He explains how these outputs can appear legitimate while being factually incorrect, and explores the cascading levels of risk this poses. The discussion moves from simple credibility issues to severe safety concerns when AI-generated data is used in critical clinical decision-making without proper guardrails.The episode concludes with a forward-looking perspective on how validation is shifting. Ashkon argues that because GenAI behavior is statistical rather than deterministic, traditional pre-market validation is no longer sufficient. Instead, a robust quality framework must include continuous post-market surveillance and real-time independent monitoring to ensure device safety and effectiveness over time.Key Timestamps01:45 - Introduction to MD&M West and the "AI Guy for SaMD," Ashkon Rasooli.04:12 - Defining Generative AI: How it differs from traditional machine learning and image recognition.06:30 - Hallucinations: Exploring failure modes where AI creates plausible but false data.08:50 - The Autonomy Scale: Applying standard 34971 to determine the level of human supervision required.12:15 - Regulatory Gaps: Why no generative AI medical devices have been cleared by the FDA yet.15:40 - Safety by Design: Using "independent verification agents" to monitor AI outputs in real-time.19:00 - The Shift to Post-Market Validation: Why 90% validation at launch requires 10% continuous monitoring.22:15 - Comparing AI to Laboratory Developed Tests (LDTs) and the role of the expert user.Quotes"Hallucinations are just a very familiar form of failure modes... where the product creates sample data that doesn't actually align with reality." - Ashkon Rasooli"Your validation plan isn't just going to be a number of activities you do that gate release to market; it is actually going to be those plus a number of activities you do after market release." - Ashkon RasooliTakeawaysRight-Size Autonomy: Match the AI’s level of independence to the risk of the application. High-risk diagnostic tools should have lower autonomy (Level 1-2), while administrative tools can operate more freely.Implement Redundancy: Use a "two is one" approach by employing an independent AI verification agent to check the primary model’s output against safety guidelines before it reaches the user.Narrow the Scope: To reduce hallucinations, limit the AI's task breadth. A model asked to write a specific security requirement is more reliable than one asked to generate an entire Design History File (DHF).Prioritize Detectability: Design UI/UX features that provide the sources or "basis" for an AI's answer, allowing human users to verify the data and catch errors more easily.Continuous Surveillance: Accept that pre-market validation cannot cover all statistical outcomes; establish a post-market "watchtower" to monitor for performance shifts and user feedback trends.ReferencesISO 14971: The standard for the application of risk management to medical devices.AAMI TIR34971: Guidance on the application of ISO 14971 to machine learning in medical devices.IEC 62304: Medical device software lifecycle processes.Etienne Nichols: LinkedIn ProfileMedTech 101: The Autonomy ScaleThink of the Autonomy Scale like the driver-assist features in a car.Level 1 is like a backup camera: It gives you data, but you are still 100% in control of the steering and braking.Level 5 is a fully self-driving car where you can sleep in the back seat.In MedTech, most generative AI is currently aiming for Level 2 or 3, where the AI suggests a "route" (like a diagnosis or a draft report), but a human "driver" (the doctor or engineer) must keep their hands on the wheel and verify every turn.SponsorsThis episode is brought to you by Greenlight Guru. Whether you are navigating the complexities of generative AI or traditional hardware, Greenlight Guru offers the only specialized Quality Management System (QMS) and Electronic Data Capture (EDC) solutions designed specifically for the medical device industry. By integrating your quality processes with clinical data collection, Greenlight Guru helps you move from "check-the-box" compliance to true quality.Feedback Call-to-ActionWe want to hear from you! How is your team implementing AI in your workflow? Do you have questions about the shifting regulatory landscape? Send your thoughts, reviews, or topic suggestions to podcast@greenlight.guru. We read every email and pride ourselves on providing personalized responses to our community of MedTech movers and shakers.

Dr. Jenny Hoffmann, MedTech executive and author of Open Up: Step Into the Leader You Are Meant to Be, joins host Etienne Nichols to discuss the evolution of leadership in the medical device industry. Drawing from her experience as a bioengineer and CEO, Dr. Hoffmann explains why the traditional model of the "rigid, perfect leader" is no longer sustainable. She shares her personal journey—from being one of the first IVF babies in the U.S. to navigating life-threatening health complications—and how these experiences shaped her mission to help others lead with authenticity.The conversation centers on the concept of "SOS moments," which Dr. Hoffmann defines as those critical points of distress or crisis that occur in both personal lives and product development. By applying her CEC framework—Curiosity, Empathy, and Connection—leaders can transform these high-pressure moments into stories of strength. This approach is particularly vital in MedTech, where the ultimate goal is to serve patients during their own most vulnerable SOS moments.Etienne and Jenny also explore the intersection of human leadership and emerging technology. While AI continues to streamline technical workflows, Dr. Hoffmann argues that human empathy and curiosity remain irreplaceable assets for innovation. The episode concludes with a practical look at the return on investment (ROI) for "opening up," demonstrating how personal connection leads to higher quality products, better team retention, and the resilience needed to survive the "messy middle" of product development.Key Timestamps00:00 - Introduction of Dr. Jenny Hoffmann and her background in MedTech and innovation.01:28 - Motivation for writing Open Up: Scaling impact through vulnerable storytelling.04:23 - The shift from the "perfectly composed" leader to the vulnerable leader.05:45 - Dr. Hoffmann’s personal origin story: Being one of the first IVF babies in the U.S.08:30 - Listening to the "whisper" and the courage required to respond to inner intuition.10:14 - The ROI of Vulnerability: How personal connection drives higher quality and team motivation.14:39 - Defining SOS moments: Turning distress signals into leadership strengths.18:42 - The CEC Method: Breaking down Curiosity, Empathy, and Connection.20:25 - AI in MedTech: Why human empathy is the one thing machines cannot replace.25:57 - Strategic Sharing vs. Oversharing: How to lead by example without losing professional boundaries.28:52 - The power of storytelling for engineers and data-driven professionals.Quotes"The leader is the first one to step out on the bridge that no one’s sure if they want to cross. You paint that vision of the bridge, and then you’re the first one to step out on it." - Dr. Hoffman"If we can put empathy first and think about how we are each a patient first... then we can uncover the real needs to solve. Then we can be more innovative." - Dr. HoffmanTakeawaysThe CEC Framework: Use Curiosity to open the mind, Empathy to open the heart, and Connection to drive outsized results in technical teams.Embrace SOS Moments: View professional crises or personal struggles as distress signals that, when analyzed with curiosity, provide the data needed to build resilience.Human-Centric AI Strategy: Leverage AI for efficiency and data processing, but double down on human empathy to solve complex patient needs that machines cannot grasp.Strategic Vulnerability: Sharing personal stories is a leadership skill. Start small by sharing "Monday morning" anecdotes before moving to deeper personal values to build team trust.The Mission Dimension: In MedTech, motivation isn't just about time and effort; it is about the "third dimension" of mission-driven impact that keeps teams moving through the "messy middle" of a project.ReferencesOpen Up: Step Into the Leader You Are Meant to Be by Dr. Jenny Hoffmann – The core book discussed, focusing on vulnerable leadership.New England Medical Innovation Center (NEMIC) – Where Dr. Hoffmann serves as Executive Director.Sure Footing Consulting – Dr. Hoffmann’s leadership and strategy firm.Etienne Nichols LinkedIn – Connect with the host.MedTech 101: SOS MomentsIn a medical context, an SOS is a distress signal indicating an immediate need for help. In leadership, Dr. Hoffmann uses "SOS moments" as an acronym for "Story of Strength" and an analogy for those times when you feel overwhelmed, fearful, or hit a major roadblock in a project (like a failed regulatory submission or a budget crisis), it can also be a moment to look back on and learn from.Just as a clinician responds to a patient’s distress signal by diagnosing the underlying issue, a MedTech leader should respond to their own "emotional SOS" by using the CEC Method.SponsorsThis episode is brought to you by Greenlight Guru. In the medical device industry, the "messy middle" of development is often where teams lose momentum. Greenlight Guru helps you stay focused on your mission by providing the only dedicated MedTech Lifecycle Excellence platform. Their QMS (Quality Management System) ensures your documentation is always audit-ready, while their EDC (Electronic Data Capture) solution streamlines clinical data management. By integrating quality and clinical data, Greenlight Guru allows leaders to spend less time on paperwork and more time on the vulnerable, innovative leadership discussed in today's episode.Feedback Call-to-ActionWe want to hear from you. How do you balance vulnerability with technical authority in your leadership role? Have you experienced an "SOS moment" that changed your career path? Please send your thoughts, reviews, or suggestions for future topics to podcast@greenlight.guru. We read every email and look forward to providing personalized responses to our listeners.

In this episode, Etienne Nichols and guest Ashkon Rasooli explore the transformative impact of AI in the medical device industry. From AI-driven diagnostics and wearable health monitors to the future of surgical robots, they delve into how these technologies are reshaping healthcare. The discussion also touches on the challenges and opportunities in validating and regulating AI within MedTech, highlighting real-world applications and predicting future trends."Validation of AI tools in MedTech requires a staged adoption to build confidence due to the inherent uncertainty in AI outcomes." - Ashkon Rasooli00:00 - Introduction to AI in MedTech05:15 - Discussing AI's deterministic vs. statistical nature12:30 - AI in diagnostics: Radiology, Cardiology, and Neurology20:45 - Wearable health monitors and patient-driven health data28:10 - The role of AI in medical device operations and manufacturing35:00 - AI at the point of care: Enhancing patient and clinician experience42:15 - Regulatory challenges and the future of AI in healthcareKey Takeaways:1. Latest MedTech Trends:The integration of AI in diagnostics is growing, particularly in radiology, cardiology, and neurology, aiding in more accurate and quicker diagnoses.Wearable health monitors are empowering patients to take control of their health data, leading to personalized healthcare solutions.2. Practical Tips for MedTech Enthusiasts:Stay informed about the latest AI advancements and regulatory guidelines to leverage AI effectively in MedTech.Consider the ethical implications and ensure bias mitigation in AI model training and deployment.3. Predictions for the Future:Increased adoption of AI across various healthcare sectors, including surgery and patient care management.Evolution of regulatory frameworks to better accommodate and oversee AI-driven medical devices.References:Ashkon Rasooli on LinkedInashkon@engeniussolutions.comEngenius SolutionsAFDO/RAPS Working GroupEtienne Nichols on LinkedInSponsors:This episode is brought to you by Greenlight Guru, a comprehensive solution designed to streamline MedTech product development and ensure regulatory compliance. Discover how Greenlight Guru can accelerate your projects at www.greenlight.guruShare your thoughts and questions with us at podcast@greenlight.guru

In this episode, we delve into the complexities and essentials of quality and regulatory roles in the medical device industry. Our esteemed guest, Jennifer Mascioli-Tudor, CEO and founder of JMT Compliance Consulting, shares her wealth of experience from top MedTech companies, underscoring the importance of proactive quality management, project management skills, and the ability to influence and communicate within organizations.Key Timestamps:[00:00:50] Introduction to Jennifer Mascioli-Tudor and her extensive background in the MedTech industry.[00:03:30] Jennifer's origin story in quality and regulatory roles.[00:07:15] The pivotal learning moments in quality management and regulatory affairs.[00:10:45] Strategies for influencing business leaders and the importance of storytelling in quality and regulatory roles.[00:16:30] The significance of human factors in product design and learning from end-user feedback.[00:21:50] Project management skills for quality and regulatory professionals.[00:25:20] The concept of 'design freeze' in the MedTech space and its impact on product development.[00:29:55] Jennifer's insights on agility and adaptability in building a quality management system.Quotes:"A really good quality and regulatory professional needs to have really good project management skills." - Jennifer Mascioli-Tudor"It's not just about the design and about the product. It's about everything ancillary that feeds into that finished medical device." - Jennifer Mascioli-TudorMedTech Trends:An emphasis on proactive quality management to ensure patient safety and product efficacy.The rising importance of human factors and user-centered design in medical device development.The shift towards integrating software and digital solutions in medical devices.Practical Tips:Quality and regulatory professionals should hone their project management skills.Communication and storytelling are key in influencing business decisions and leadership.Always present solutions and alternatives when addressing compliance challenges.References:JMT Compliance ConsultingJennifer Mascioli-Tudor on LinkedInEtienne Nichols on LinkedInGreenlight Guru’s platform for Quality Management & Clinical InvestigationsQuestions for the Audience:Discussion: "How do you envision MedTech changing the landscape of healthcare in the next decade?"Feedback:Love the episode? Have suggestions or topics you’d like to hear about? Email us at podcast@greenlight.guru and leave a review on iTunes!Sponsors:This episode is brought to you by Greenlight Guru, the only quality management software designed specifically for the medical device industry. Streamline your process and foster innovation with Greenlight Guru’s intuitive platform!

In this episode, Etienne Nichols sits down with Michelle Wu, Founder and CEO of Nyquist AI and one of the top 100 women in AI, to discuss the transformative state of artificial intelligence within the MedTech regulatory and quality space. Reflecting on her recent personal experience as a surgical patient, Michelle shares a unique perspective on the critical importance of the devices and quality systems that keep the industry running.The conversation dives deep into the "Great Rewiring" of the medical device industry. Michelle outlines how we have moved past the initial phase of AI skepticism and "AI fatigue" into a period of hyper-acceleration. With the introduction of the FDA’s ELSA and the implementation of the EU AI Act, the industry has reached a point where AI is no longer a side project but a fundamental requirement for operational longevity.Finally, the episode provides a roadmap for both organizations and individual contributors. Michelle introduces her "Holy Trinity" framework for AI implementation—Data, Workflow, and Agents—and explains why the next two years will be defined by the "Invisible Colleague" or AI copilot. For junior professionals, the message is clear: knowledge is now a commodity, and the real value lies in the ability to ask high-quality, strategic questions.Key Timestamps00:00 – Introduction and Michelle Wu’s background in MedTech and AI.03:45 – A founder’s perspective: Michelle’s personal experience in the OR seeing her clients' devices.08:12 – The 2025 Inflection Point: FDA ELSA, EU AI Act, and global AI expectations.11:50 – From billable hours to value-based output: How AI is disrupting the consulting business model.15:35 – Micro-timestamp: 2026 Predictions. The shift toward universal AI Copilots and Agents for every MedTech role.18:22 – The Holy Trinity of AI: Breaking down Data Layers, Workflow Automation, and AI Agents.22:10 – Case Study: How a top-tier MedTech company automated 17,000 quality and regulatory tasks.27:45 – The 56.8% Salary Premium: Why AI literacy is the most important skill for young RAQA professionals.31:15 – Shifting from memorization to "Clarity of Mind" and high-quality inquiry.Quotes"Knowledge is a commodity now. Previously, regulatory consultants or professionals stood out by their knowledge. Now, with AI leveling the field, the capability lies in those who can ask high-quality questions." - Michelle Wu, Nyquist AITakeawaysAI Literacy is a Financial Multiplier: LinkedIn data shows that non-engineering knowledge workers with AI literacy can command a salary premium of up to 56.8%.The 80/20 Rule of Automation: Approximately 80% of current RAQA tasks are tedious, manual, or administrative. Successful teams are using AI to automate that 80%, allowing humans to focus on the 20% that is strategic and high-value.The Three-Layer AI Strategy: To effectively implement AI, companies should look at the Data Layer (intelligence), the Workflow Layer (automation of specific tasks), and the Agent Layer (autonomous "employees").Value-Based Billing: As AI reduces the time required for regulatory submissions and gap analyses, the industry is moving away from the "billable hour" toward pricing based on the value and quality of the output.ReferencesNyquist AI: Michelle Wu’s platform specializing in global regulatory intelligence and AI-driven workflow automation for MedTech.FDA ELSA: The FDA’s internal AI tool that marked a significant shift in the agency's embrace of the technology.IMDRF GMLP: Good Machine Learning Practice guidelines for AI-enabled medical devices.EU AI Act: The first comprehensive legal framework for AI, affecting MedTech compliance timelines.Etienne Nichols: Connect with Etienne on LinkedIn.MedTech 101: AI Agents vs. AI ChatbotsWhile many people are familiar with AI Chatbots (like the early versions of ChatGPT), the industry is moving toward AI Agents.Think of a Chatbot like a very smart encyclopedia. You ask it a question about a 510(k) submission, and it gives you information.An AI Agent, however, is like an AI Intern. It doesn't just give you information; it performs a multi-step task. For example, you can tell an Agent to "find the three most relevant predicates for this new device, summarize their 510(k) summaries, and draft a gap analysis table." The Agent "thinks" through the steps and delivers a finished product, not just a response.SponsorsThis episode is brought to you by Greenlight Guru. As Michelle and Etienne discussed, the future of MedTech is driven by data and efficiency. Whether you are navigating the complexities of the EU AI Act or scaling your R&D, Greenlight Guru’s QMS (Quality Management System) and EDC (Electronic Data Capture) solutions provide the structured data foundation necessary to leverage AI effectively. By integrating quality and clinical data, Greenlight Guru helps you move from "reactive" compliance to "proactive" innovation.Feedback Call-to-ActionWe want to hear from you! How is your team currently leveraging AI in your regulatory or quality workflows? Are you feeling the "AI fatigue," or are you seeing the "salary premium" Michelle mentioned?Send your thoughts, guest suggestions, or specific questions to podcast@greenlight.guru. Etienne personally reads and responds to listener feedback, and we would love to feature your insights in a future episode.

The FDA's new Quality Management System Regulation (QMSR), which replaces the 21 CFR Part 820 Quality System Regulation (QSR) and incorporates ISO 13485:2016 by reference, represents a significant harmonization effort in the medical device industry. While viewed by some as a mere streamlining, the change is mandatory, with an effective and fully enforceable date of February 2, 2026. The episode addresses industry complacency and details critical steps manufacturers must take immediately.The episode debunks the myth that familiar quality documents like the DHF, DMR, and DHR are being eliminated. While the specific terms are removed from the regulation's language, their substance is retained and mapped to new, ISO-aligned conceptual requirements: the Device Master Record (DMR) becomes the Medical Device File (MDF), the Design History File (DHF) becomes the Design and Development File (DDP), and the Device History Record (DHR) is captured in the Batch or Lot Record. The host emphasizes that internal documents can retain the old terminology, provided a clear regulatory mapping is established.Crucially, compliance requires more than just an ISO 13485 certificate. Two major philosophical shifts must be addressed: the explicit requirement for integrating lifecycle risk management as the DNA of the entire QMS, and the loss of the audit privilege, which makes internal audit reports, supplier audit reports, and management review records inspectable regulatory evidence. Furthermore, manufacturers must comply with retained, US-specific requirements under the QMSR's prevalence rule, especially concerning mandatory record content (§ 820.35) and specific labeling and packaging controls (§ 820.45).Key Timestamps[0:50] QMSR: The biggest shakeup to US quality requirements since 1996.[2:00] Effective Date: February 2, 2026—the clock is ticking.[2:42] The Goal: Harmonization with ISO 13485:2016 to reduce redundancy for global manufacturers.[3:50] Myth 1 Busted: The FDA is eliminating the DHF, DMR, and DHR (Documentation Dissolution).[5:10] Terminology Shift: DMR > Medical Device File (MDF, ISO 13485 Clause 4.2.3).[6:30] Terminology Shift: DHF > Design and Development File (DDP, ISO 13485 Clause 7.3.10).[7:40] Terminology Shift: DHR > Batch or Lot Record (ISO 13485 Clause 7.5.1).[8:40] The Practical Takeaway: Internal naming is fine, but regulatory mapping is mandatory.[10:30] Critical Shift 1: Risk Management is the DNA of the QMS—Explicitly required across all clauses.[13:00] Critical Shift 2: Loss of the Audit Privilege—Internal audit and management review records are now inspectable.[17:00] Critical Shift 3: Retained FDA Specifications (Prevalence Rule).[17:35] Retained Req. A: Mandatory Record Keeping Content (21 CFR Part 820.35)—UDI/UPC in complaint/service records.[19:00] Retained Req. B: Extended Record Retention Period (Device life, no less than two years).[20:10] Retained Req. C: Specific Labeling and Packaging Controls (21 CFR Part 820.45)—Inspection for accuracy.[22:00] Immediate Action Plan: Gap analysis and restructuring to the new terminology.Quotes"Your internal audit reports, your management review minutes, if you were expecting to keep those shielded from any outside eyes, they are now inspectable regulatory evidence." - Etienne NicholsTakeawaysMandatory Regulatory Mapping: Manufacturers must conduct a thorough mapping exercise to ensure their existing DMR, DHF, and DHR content fulfills the new requirements of the Medical Device File (MDF), Design and Development File (DDP), and Batch/Lot Records, respectively.Embed Lifecycle Risk Management: The QMSR requires a holistic, lifecycle approach to risk management, making it an explicit core component of all QMS clauses (e.g., supplier controls, design and development), moving beyond isolated, perfunctory steps.Prepare for Full Documentation Exposure (Regulatory): Recognize that the former privilege is gone; internal audit reports, supplier audit reports, and management review records are now subject to routine FDA inspection. Draft these documents with the utmost rigor and awareness of their new status as regulatory evidence.Confirm Compliance with FDA Retained Sections: ISO 13485 certification is not enough. You must address the US-specific requirements retained under the prevalence rule, particularly the mandatory inclusion of UDI/UPC in complaint records (§ 820.35) and the strict labeling/packaging inspection controls (§ 820.45).Transition is Immediate: The compliance date of February 2, 2026, is a hard deadline. Proactive gap analysis, process restructuring, and staff training based on the QMSR's requirements and the FDA's preamble are essential for uninterrupted market access.ReferencesISO 13485:2016: The international Quality Management System standard for medical devices incorporated by reference into the QMSR.21 CFR Part 820 (New QMSR): The revised Code of Federal Regulations that replaces the QSR, incorporating ISO 13485 and retaining US-specific supplemental provisions.21 CFR Part 820.35 (Control of Records): Retained section requiring specific content, like UDI/UPC, for complaint and service records.21 CFR Part 820.45 (Device Labeling and Packaging Controls): Retained section requiring documented procedures for inspecting labeling and packaging accuracy.QMSR Preamble: The FDA's detailed commentary and response to comments, which is crucial for understanding the Agency's interpretive thinking behind the new rule.Etienne Nichols' LinkedIn: https://www.linkedin.com/in/etienne-nichols/MedTech 101 SectionWhat is the "Prevalence Rule"?The Prevalence Rule is a key concept in the new Quality Management System Regulation (QMSR) that clarifies which set of rules takes priority. Since the FDA is incorporating the international standard ISO 13485:2016 by reference, a conflict could arise between the ISO standard and existing U.S. law. The Prevalence Rule dictates that in any area of conflict, the U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations (like those retained in 21 CFR Part 820) will always supersede the ISO 13485 requirement. Think of it like a recipe: ISO 13485 is the main set of instructions, but the retained 21 CFR sections are non-negotiable, mandatory additions or modifications that must be followed regardless of what the main instructions say. This is why mere ISO certification does not guarantee QMSR compliance.SponsorsThis episode is brought to you by Greenlight Guru. As the medical device industry faces the significant shift to the QMSR, your QMS needs to be audit-ready and easy to update. Greenlight Guru offers an all-in-one MedTech lifecycle excellence platform with specialized QMS and EDC solutions. Our electronic Quality Management System (eQMS) is built to facilitate the traceability and document control necessary to manage the new ISO-aligned terminology and retained FDA...

The MedTech talent landscape has undergone a significant "reset" in the two years since Elena Kyria, founder and CEO of Elemed, last joined the podcast. Driven by factors like the rise of AI, economic volatility, and post-pandemic shifts, the dynamic has swung from a "war for talent" (many jobs, few candidates) to a market flooded with applicants, often overwhelming internal recruitment teams. This shift, exacerbated by simple application processes like LinkedIn's Easy Apply, makes it challenging for good candidates to cut through the noise and for companies to manage high application volumes.To thrive in this new environment, MedTech professionals, particularly those in Quality Assurance (QA) and Regulatory Affairs (RA), must expand their focus beyond technical competence. Elena stresses the growing importance of transverse skills (the essential human skills like communication, negotiation, and leadership) and, critically, AI literacy. With the pressure on companies to "do more with less," AI is creating an environment where smaller, highly productive teams are favored. This doesn't mean roles will disappear, but professionals must embrace technology to eliminate tedious tasks and focus on high-value, strategic work.Navigating the job market now requires a more intentional and proactive approach, especially to access the hidden job market where the best unadvertised roles reside. Tactics include direct networking with hiring managers and active professional branding. Furthermore, the global regulatory environment's fragmentation—especially between the US (FDA) and EU (MDR/IVDR)—is impacting how companies build their teams, favoring remote work and strategic location choices that factor in the local talent pool and employment laws.Key Timestamps1:50 - The MedTech Talent Shift: From "War for Talent" to a "Reset"4:45 - The impact of high volume and "easy apply" on candidate experience6:15 - Immediate disqualification criteria and "gaming" the application system7:35 - Strategies for accessing the hidden job market (networking and strategy)9:20 - The controversial impact of AI on QA/RA roles and the need for efficiency11:30 - Future-proofing your career: Why leaders and junior professionals must embrace AI13:55 - Understanding transverse skills (soft skills) and business acumen15:40 - The QA/RA role in the age of AI: Focusing on the 30% of high-value expertise17:00 - Tactics for achieving AI literacy: Small wins, experimentation, and habit stacking19:45 - Why the "hidden job market" exists (confidentiality, exclusivity, and pipeline)21:30 - Positioning yourself externally: The power of active contribution on LinkedIn23:45 - The importance of speaking at industry events (e.g., RAPS) to build credibility24:55 - Strategic advice for founders building remote, global teams26:15 - The impact of US vs. EU regulatory fragmentation on talent selectionQuotes“It's not going to be enough to just be good at your job. You're going to need to have a little bit more understanding of how to position yourself, how to brand yourself, how building skills outside of just your technical competency [is important].” - Elena Kyria“This is a massive opportunity... to step up and get started... you can use the technology but then you're focused on strategy, relationships, [and] the human side of it versus the people that are still very manual.” - Elena KyriaTakeawaysPrioritize AI Literacy: MedTech professionals must proactively experiment with AI tools (like note-takers and regulatory intelligence systems) to automate up to 70% of tedious tasks. Waiting for formal company training risks falling behind competitors who are already seeing a compounding effect from daily micro-improvements.Master Transverse Skills: Beyond technical QA/RA knowledge, focus on building "hard soft skills" like negotiation, communication, leadership, and financial/business acumen. These are the differentiating skills that AI cannot replicate and will define the strategic value of the future professional.Shift from Lurker to Contributor: Use LinkedIn strategically. Instead of passively scrolling, actively engage by adding meaningful, subject-matter expert comments to relevant posts. This builds credibility and positions you as a known contributor, enhancing your professional brand.Tap into the Hidden Job Market: Rely less on mass applications and more on strategic networking, building long-term relationships, and direct outreach to hiring managers. The best, often confidential, roles are frequently filled through these non-advertised channels.Global Teams Require Legal Due Diligence: Founders building remote teams must be acutely aware of local employment laws and benefits (e.g., maternity leave differences) in each geography. Talent decisions shouldn't just be based on cost or tax benefits but must factor in the available skill density in that location.ReferencesElemed: Elena Kyria's consultancy focused on MedTech executive hiring and recruitment strategy.RAPS (Regulatory Affairs Professional Society): Mentioned as a key platform for professional development and speaking opportunities within the MedTech regulatory field.Greenlight Guru QMS & EDC Solutions: Greenlight Guru's Quality Management System (QMS) helps MedTech companies simplify compliance, while their Electronic Data Capture (EDC) platform streamlines clinical trial data management.Etienne Nichols' LinkedIn: linkedin.com/in/etiennenicholsMedTech 101 SectionTransverse Skills vs. Technical SkillsIn the MedTech industry, we often talk about technical skills—the specific knowledge needed for a job, such as knowing the difference between the FDA's 510(k) and the EU's MDR requirements.Transverse Skills (historically called "soft skills") are the human abilities that apply across all roles and industries, and they are becoming the most critical skills for MedTech professionals in the age of AI.Simple Analogy: Think of a medical device engineer:Technical Skill: Being able to design a circuit board or write a V&V protocol.Transverse Skill: Being able to clearly communicate the risks of that circuit board design to the management team, or negotiate with a supplier on quality specifications.As AI takes over tasks like drafting initial documents or summarizing regulations, the uniquely human skills—like critical thinking, ethical judgment, leadership, and strategic communication—are what add true, irreplaceable value to a MedTech company.Feedback Call-to-ActionDid this episode shift your perspective on AI or the job market? Your feedback helps us shape future content. We are committed to providing personalized and actionable advice to MedTech professionals globally. Please send your thoughts, reviews, or suggestions for future topics directly to podcast@greenlight.guru.SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru. In a market where MedTech talent must be highly productive and efficient, your tools should support that goal. Greenlight Guru offers solutions that help your teams do more with less: our industry-specific QMS streamlines your compliance and quality processes, while our EDC solution digitizes and simplifies your clinical data capture. Visit greenlight.guru to learn how you can upgrade your system to match your highly skilled workforce.

This episode tackles the complex challenge of applying the hardware-centric clauses of ISO 13485 to Software as a Medical Device (SaMD). Adnan Ashfaq, founder of Simply Medica, joins Etienne Nichols to dissect how traditional standards intended for physical manufacturing must be creatively interpreted for the virtual world of software development, where apps update weekly and cloud-based systems evolve in real-time. The conversation zeroes in on the often-muddy areas of production and service provision (Clause 7.5), emphasizing that these clauses are far from non-applicable, requiring a "virtual manufacturing space" mindset.A significant focus is placed on the Software of Unknown Provenance (SOUP), treating these building blocks as purchased components that require robust supplier evaluation and validation, bridging Clause 7.5 (production) with Clause 7.4 (purchasing). The discussion extends to crucial concepts like the Software Bill of Materials (SBoM), the complexity of Agile vs. Waterfall approaches within the standard's framework, and the essential role of the new FDA Computer Software Assurance (CSA) guidance in risk assessment.Beyond production, the experts explore the application of resource management (Clause 6), specifically addressing infrastructure, contamination control (malware/ransomware), and the critical need for a well-documented Design Transfer to Production (Clause 7.3.8) evidenced by a complete software release package, including all 62304 requirements. The episode provides actionable insights for quality and compliance professionals struggling to maintain speed and innovation while strictly adhering to regulatory requirements.Key Timestamps01:45 - The changing landscape: Why traditional MedTech rules struggle with modern software updates.03:50 - Historical context of ISO 13485 and its non-distinction between hardware/software.05:05 - Starting Point: Clause 7.5 (Production and Service Provision) and the "Virtual Manufacturing Space" concept.06:20 - Unpacking Software of Unknown Provenance (SOUP) and its link to Clause 7.4 (Purchasing).08:35 - The necessity of validating the development environment (GitHub/GitLab) and building blocks.11:10 - Applying Clause 4.1.6 (Software Validation) to SOUP items and master validation plans.12:20 - Applicable vs. Non-Applicable Clauses: Sterilization/Cleanliness vs. Installation.13:55 - Clause 4.2.3 (Medical Device File) for SaMD: E-labels, UDI, System Architecture, and SBoM.16:30 - Cybersecurity controls and the manufacturer's responsibility for identifying state-of-the-art standards.17:35 - Defining "Production" for continuously updating software and managing significant vs. non-significant changes.20:15 - Clash of Standards: Agile development, ISO 13485, and the missing documentation for version control risk assessment.21:30 - Clause 6.3 & 6.4 (Resource & Work Environment): Looking at data security, access controls, and contamination (malware/ransomware).24:45 - Clause 7.3.8 (Design Transfer to Production): The need for a formal software release package and the importance of the Software Design Trace Matrix.26:00 - The 16 essential documents needed to meet IEC 62304 requirements.27:10 - Production controls when the user influences the outcome (customizable features, disclaimers).Quotes"So my starting point really in this conversation is to cherry pick some of those clauses from ISO 13485, which are more akin to production. And then how do we then unpack that and apply it with medical device software in mind?" — Adnan Ashfaq"You've got to look at data corruption, you've got to look at unauthorized code, you've got to look at version controlling malware or ransomware, you've got to look at that as well. That's all part of [contamination control, Clause 6.4.2]." — Adnan AshfaqTakeawaysAdopt a "Virtual Manufacturing Space" Mindset: Treat your development environment (e.g., source control systems like GitHub/GitLab, compilers, cloud platforms) as a production floor that requires the same level of validation and control as a physical cleanroom or factory floor, satisfying ISO 13485 Clause 7.5.Validate SOUP as Purchased Products: Any Software of Unknown Provenance (SOUP) or open-source components must be treated as "purchased product" under Clause 7.4, requiring documented supplier verification, impact assessment, and validation (or documented rationale for non-validation) before integration into your SaMD.Contamination Control is Cybersecurity: ISO 13485 Clause 6.4.2, Contamination Control, must be applied to the digital sphere. This includes safeguards against malware, ransomware, unauthorized code, and data corruption, emphasizing the non-negotiable need for robust cybersecurity controls in your Quality Management System (QMS).Formalize the Software Bill of Materials (SBoM): The SBoM, detailing all software components, libraries, dependencies, and their version controls, is a key deliverable under Clause 4.2.3 (Medical Device File), acting as the digital equivalent of a Bill of Materials for Design Transfer to Production (Clause 7.3.8).Bridge Agile with Documentation: When using Agile development, ensure every iteration, bug fix, or patch includes a documented risk assessment (connecting to ISO 14971) and change history to satisfy ISO 13485’s traceability and control requirements, preventing potential non-conformances in audit.ReferencesEtienne Nichols' LinkedIn: linkedin.com/in/etiennenicholsISO 13485:2016 (specifically Clauses 7.5, 7.4, 4.2.3, 6.3, 6.4, 7.3.8)IEC 62304 (Medical device software – Software life cycle processes)FDA Computer Software Assurance (CSA) Guidance: The new guidance replacing older process validation guidance, focusing on a risk-based approach (High Risk vs. Low Risk) for validating software tools.AAMI TIR 45 (Guidance on the use of agile practices in the development of medical device software)MedTech 101 SectionSoftware of Unknown Provenance (SOUP)SOUP refers to software components that have been developed for purposes other than being part of the medical device, and for which the developer did not use a medical device quality management system (QMS) process. In simple terms, it's off-the-shelf software (like an open-source library, a commercial operating system, or a third-party module) that you integrate into your SaMD.Analogy: If you are building a custom, high-end car (your medical device), the engine block (the SaMD code) is custom-made. However, you decide to use commercially available tires, a standard battery, and a third-party GPS system (the SOUP items). While convenient, you can't be 100% sure how those other developers built them. To use them in your regulated medical product, you must perform your own testing and validation (verification) on the SOUP components to ensure they work reliably and safely within your device's specific intended use, treating them as if you purchased them from an outside supplier under Clause 7.4.Feedback Call-to-ActionWe thrive on your expertise and insights. If you have questions about applying ISO 13485 to your specific SaMD project, or if you'd like to suggest a topic for a future deep-dive, please send us an email. We read every message and offer personalized responses to help you navigate the complexities of MedTech compliance.Contact us at: podcast@greenlight.guruSponsorsThis episode discussing the critical balance of innovation and compliance in SaMD is brought to you by Greenlight Guru. In a world where software updates are weekly, using antiquated paper-based or general-purpose QMS systems is a compliance risk. Greenlight Guru offers MedTech-specific solutions, including a leading QMS platform and an advanced EDC solution, that are designed to handle the complexity of modern device development, like seamless traceability for your Software Bill of Materials and automated audit trails, ensuring you stay compliant with standards like ISO 13485 and IEC 62304.

In this episode of the Global Medical Device Podcast, Etienne Nichols is joined by Kavetha Ram, a seasoned expert in health and pharmaceutical sciences and the regulatory department leader at Spectra Medical Devices. Together, they delve into how new regulatory affairs professionals can get started in a career of medical device regulations and the shifting field of MedTech. The discussion offers a roadmap for professionals to navigate and thrive amidst these shifts. The episode is a treasure trove of knowledge for anyone looking to stay ahead in the MedTech realm.Key Timestamps:[00:00:30] Introduction to Kavetha Ram and the episode's focus[00:05:15] Discussion on the challenges and opportunities of new regulations[00:10:40] Insights into the importance of confidence and adaptability in the regulatory field[00:15:20] Kavetha's journey and advice for emerging professionals[00:25:00] The role of innovation and collaboration in MedTech advancements[00:35:10] Strategies for professionals to stay relevant and proactiveQuotes:"Regulations are not just hurdles; they are stepping stones to innovation and safety in MedTech." - Kavetha Ram"Embracing change in regulations is not an option but a necessity for MedTech's future." - Etienne Nichols"Diversity in teams isn't just about varied backgrounds; it's about unlocking unique perspectives that drive innovation." - Kavetha RamKey Takeaways:Insights into MedTech Trends:Regulatory changes are both a challenge and an opportunity for innovation.Practical Tips for MedTech Enthusiasts:Stay updated with regulatory changes and understand their implications.Engage in continuous learning and skill development.Foster collaboration across disciplines to enhance innovation.References:Kavetha Ram's LinkedIn ProfileEtienne Nichols' LinkedIn ProfileGreenlight GuruQuestions for the Audience:"What advice do you have for budding Regulatory Affairs professionals?"Reach out to us and let us know what you thought of the episode at podcast@greenlight.guruAlso, if you enjoyed this episode, please leave us a review on iTunes!Sponsors:This episode is brought to you by Greenlight Guru, the only quality management software designed specifically for the medical device industry. Greenlight Guru's platform streamlines product development and compliance, making the process more efficient and less risky. Discover how Greenlight Guru can accelerate your product development at www.greenlight.guru.

This episode of the Global Medical Device Podcast features a compelling conversation with Perry Parendo, a seasoned expert in product development and project management within the MedTech sector. Host Etienne Nichols and Perry delve into the challenges and opportunities facing medical device development, emphasizing the critical role of agile practices, risk management, and the necessity for a patient-focused approach. The discussion sheds light on how companies can navigate regulatory landscapes, manage project risks, and drive innovation to enhance patient care.Key Timestamps:00:00:15 - Introduction of Perry Parendo and the episode's focus00:03:50 - Discussing the challenges of MedTech product development and regulatory hurdles00:12:20 - Agile methodologies vs. traditional project management in MedTech00:22:35 - The importance of risk management and Monte Carlo simulation in project planning00:34:10 - Perry's perspective on innovation, compliance, and balancing project priorities00:45:55 - Strategies for efficient and effective product development processesQuotes:"We're so focused from a compliance point of view on patient and health risk, we're not focused on project risk. And when I worked in the defense industry, we were hugely focused on project risk," Perry Parendo"There's waterfall, there's agile, there's Toyota, there's set based design, and there's APQP in the automotive industry. They're all a blend. There's no organization that's doing purely the theoretical of any one of those processes," Perry ParendoTakeawaysInsights on MedTech Trends:The convergence of agile and traditional methodologies tailored to MedTech's unique demands.The rising importance of advanced risk management techniques, like Monte Carlo simulations, in navigating project uncertainties.A call for innovation that transcends regulatory compliance to genuinely benefit patient care.Practical Tips for Listeners:Adopt a flexible approach to project management by integrating various methodologies based on project needs.Prioritize risk management early in the development process to foresee and mitigate potential challenges.Always align product development objectives with the ultimate goal of improving patient outcomes.Questions for Future Developments:How will evolving regulatory standards shape the next generation of medical devices?What role will patient feedback play in the design and development of future MedTech innovations?Can MedTech sustain its pace of innovation while ensuring safety and compliance?References:Perry Parendo on LinkedInEtienne Nichols on LinkedInBehavioral Grooves podcast with Annie Duke - Thinking in BetsBook - Someday is Today, Ron RichardYoutube video - the Heartbeat of New Product DevelopmentQuality Culture for Product Design SuccessDesign News ColumnsPractical Monte Carlo AnalysisQuestions for the Audience:Poll: Which MedTech advancement do you believe will have the most significant impact on healthcare in the next decade?Discussion: How do you envision the future of healthcare changing with the continuous integration of MedTech innovations?We're eager to hear your thoughts on this episode and your suggestions for future topics. Please share your feedback and leave us a review on iTunes!For in-depth discussions and questions, email us at podcast@greenlight.guruSponsors:This episode is brought to you by Greenlight Guru, the only quality management system (QMS) and electronic data capture (EDC) software designed specifically for the medical device industry. Make your product development process smoother, faster, and compliant with Greenlight Guru. Discover the difference at www.greenlight.guru

In this episode of the Global Medical Device Podcast, we’re joined by Elena Kyria, a talent acquisition specialist and CEO of Elemed. Elena delves into what it takes to climb the career ladder in the medtech industry, whether you're early or late in your career journey. Our host, Etienne Nichols, engages in a rich discussion on career paths, leveraging personal strengths, and the importance of networking and personal branding.Quotes"If you're not talking about the value that you add, how is anybody going to know what impact you're having?" - Elena Kyria"Everything's uncertain really, isn't it? What you've got to have is a clear sense of forwards and just have a goal." - Elena Kyria"Nobody goes to the gym and looks at the weights and gets fit. You have to do the reps." - Elena KyriaTakeawaysNetworking is Key: It's not just what you know, but who knows you and what they know you're doing.Visibility of Achievements: Share your successes within your company; if you don't, others may not recognize your contributions.Defining Success: Success doesn't always mean reaching the VP level; it's about personal satisfaction and contribution.Strengths and Weaknesses: Focus on your strengths but be aware of your weaknesses and compensate with your team.Career Paths: Understand the different career paths (leadership, expert, generalist) and what they entail for growth.Communication Skills: Strong communication skills are paramount for leadership and for translating technical details to a broader audience.Continuous Learning: Always seek new knowledge and experiences, no matter where you are in your career.Adaptability: Be prepared to pivot and adapt to changes within the industry and your career.Take Action: Don't just reflect on advice; apply it to make actual changes in your career approach.Reference Links:Elena Kyria's LinkedInElemedWorking GeniusGreenlight GuruEtienne Nichols' LinkedInRemember to engage with the hosts and guests on LinkedIn for feedback and further discussions. Don’t forget to leave a review on iTunes!*Interested in sponsoring an episode? Use this form and let us know!

This episode dives into the complex and often misunderstood MedTech market in China, featuring Elaine Tan, creator of MedTech Chopsticks, who translates the nation’s stringent regulatory language into actionable insights. Elaine and host Etienne Nichols discuss the substantial risks and rewards of bringing a medical device to China, highlighting the country's rapid execution, intense internal competition, and the shift from low-end manufacturing to a focus on high-level innovation. A key risk is that existing international certifications (like ISO and IEC) do not guarantee compliance, requiring local type testing and adherence to specific national standards.The conversation addresses how global medical device companies can structure their strategy amid ongoing geopolitical shifts and the "China for China" policy, which favors domestic products through initiatives like the Volume-Based Procurement (VBP). Strategies such as the dual-strategy approach—localizing low-consumable manufacturing while protecting high-technology IP through joint ventures or careful CMO/CDMO selection—are explored as pragmatic ways to secure market presence and margin. Understanding the regulatory landscape, particularly the NMPA's 2021 overhaul, is crucial for success.Finally, Elaine provides practical guidance for regulatory professionals intimidated by the market. This includes understanding the specific regulatory and clinical pathways, performing a gap analysis against Chinese standards (Product Technical Requirements or PTR), and the critical process of selecting and qualifying a local partner/agent. Elaine reveals a specific, often overlooked hurdle: the agent must possess an NMPA-approved CA (Certification Authorization) USB key to electronically submit registration files on behalf of the foreign manufacturer, a critical piece of the submission puzzle. The discussion also touches on leveraging special zones, like the Hainan Free Trade Zone, for crucial real-world data collection applicable to the Chinese population.Key Timestamps[02:40] Introduction to Elaine Tan, MedTech Chopsticks, and the show’s focus on the China market.[05:05] High-level risks and rewards: complexity, lengthy registration, local testing requirements, and IP concerns.[08:08] Discussing the NMPA's 2021 regulatory overhaul and the geopolitical shift toward "China for China."[11:00] The Dual Strategy approach: balancing low-end localization with protecting high-tech IP.[14:48] Using CDMOs/CMOs for pilot projects to manage financial investment risk.[16:20] Leveraging the Hainan Free Trade Zone (Bo’ao region) for pre-market clinical data collection and urgent needs product access.[18:42] Ethological differences and their impact on clinical data justification (e.g., Pulse Oximeters).[20:17] NMPA predicate search: The importance of using the Chinese Classification Catalog to find registered, local predicate devices.[23:00] Guidance for overwhelmed regulatory professionals entering the China market: Clinical strategy and Product Technical Requirements (PTR).[25:52] Pitfalls in partner selection: The necessity of the NMPA-approved CA (Certification Authorization) USB key for submissions.[29:30] Partner qualification: Ensuring the agent can support Post-Market Surveillance (PMS) and QMS self-inspection requirements.[30:52] Final pitfall: International compliance (ISO/IEC) does not automatically ensure China compliance.Quotes"The requirements that you have fulfilled in the earlier stages might not be sufficient to enter market. They need to have local testing [and] need to compliant with the local standard." - Elaine Tan"For China, NMPA would like to actually emphasize that you need to select a predicate which has been approved in China markets already... This product have to be already registered to be valid and to be applicable to be used as a predicate device." - Elaine TanTakeawaysMandatory Localization is Key: Be aware that high international compliance (ISO, IEC) does not substitute for mandatory local type testing and adherence to China's specific Product Technical Requirements (PTR). Factor this into your R&D and budget early on.Employ a Dual-Strategy for IP: For high-tech, innovative products, avoid placing core IP entirely within China. Consider a hybrid structure using joint ventures, strategic CMO/CDMO partnerships, or utilizing international patents to safeguard your know-how while localizing the manufacturing of less innovative consumables.Leverage Special Pathways: Explore regional initiatives like the Hainan Free Trade Zone (Bo’ao region). This area allows for early, pre-market clinical collaborations to collect essential real-world data on the Chinese population, which is often required to justify clinical significance based on ethological differences (differences based on race/demographic).Vet Your China Agent Rigorously: The most critical qualification for your foreign regulatory agent is not just experience, but their possession of the NMPA-issued CA (Certification Authorization) USB key. Without this physical credential, they cannot electronically submit your registration files.Understand NMPA Predicate Rules: When developing your clinical strategy, the NMPA requires the selection of a predicate device that is already approved and registered in the Chinese market, regardless of whether it is domestic or foreign-made. Use the NMPA Classification Catalog to find the correct "common name" to search their database effectively.References:NMPA (National Medical Products Administration): The regulatory authority in China responsible for medical device approvals and oversight.Product Technical Requirements (PTR): A key NMPA requirement document defining the specific performance, testing, and compliance standards for a medical device in China.Hainan Free Trade Zone (Bo'ao region): A special economic and medical tourism zone that permits the use of certain internationally approved, urgently needed medical devices before formal NMPA registration, allowing for local clinical data collection.Elaine Tan's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneMedTech 101 SectionEthological Differences: In the context of medical devices and clinical trials, "ethological differences" refers to the variations in biological, anatomical, or physiological characteristics between different human races or demographic populations. A classic example is a pulse oximeter: because the device measures oxygen saturation based on light absorption in the blood, the different skin tones across populations can affect the light's absorption rate. Therefore, data collected only on one demographic may be insufficient to prove clinical safety and efficacy in another, requiring local testing for products sensitive to these population differences.CA (Certification Authorization) USB Key: This is a crucial physical piece of hardware, similar to a security token, issued by the NMPA to accredited foreign manufacturer agents. It functions as a unique digital signature and login credential, which must be plugged into a computer for the agent to access the NMPA's electronic platform and successfully submit all regulatory and registration documents. Its possession is non-negotiable for an agent handling foreign medical device registrations.Feedback Call-to-ActionWe want to hear from you! Your feedback is invaluable in shaping the future of the Global Medical Device Podcast. Did this discussion help clarify your strategy for the Chinese market? Do you have experience with the NMPA's CA key or the Hainan Free Trade Zone? Send your comments, feedback, or suggestions for future topics directly to podcast@greenlight.guru. We emphasize personalized responses, so reach out—we’d love to hear your insights.SponsorsThis episode is brought to you by Greenlight Guru, the only MedTech-specific platform providing both QMS (Quality Management System) and EDC (Electronic Data Capture) solutions. Navigating the regulatory complexities of the Chinese market, including meeting the rigorous Product Technical Requirements (PTR) and managing extensive documentation, demands a specialized system. Greenlight Guru's platform is designed to streamline compliance for multiple global markets, ensuring you have a secure and compliant foundation for your device’s entire lifecycle, whether you're dealing with local type testing or

This "Meet the Guru" episode introduces Alex Naber, a seasoned medical device consultant at Greenlight Guru, offering listeners a deep dive into his background and expertise. Alex shares his journey, beginning in bioengineering and progressing through roles in complaints, field action, design quality, and post-market quality management at a major orthopedic company (Zimmer Biomet). His experience highlights the crucial need for expert guidance in navigating complex MedTech regulations and quality management system (QMS) pathways.Alex and host Etienne Nichols discuss the immense value of having a diverse internal team of consultants to draw from—a collective knowledge base that helps solve complex problems for clients. They emphasize that quality professionals don't need to know "everything" but rather must have the right resources and a "beginner's mindset" to guide companies effectively. The conversation also explores how modern software, like Greenlight Guru's QMS and EDC solutions, eliminates common industry pain points, such as fragmented, error-prone spreadsheet-based design controls by building true, linked traceability directly into the eQMS.Finally, the discussion touches on the philosophical "why" of the medical device industry: the patient. Alex shares a personal story about how orthopedics improved his grandfather's quality of life, underscoring the importance of maintaining a patient-first ethos. They conclude by discussing the upcoming QMSR transition, reassuring listeners that compliance is manageable, especially for those already adhering to ISO 13485.Key Timestamps[01:50] Alex Naber's MedTech Career Path: From Bioengineering to Design Quality and Post-Market Management.[04:30] The Power of Pooled Expertise: Why Greenlight Guru's Consultant Team is a "Sherpa up the mountain."[07:35] The Problem with Spreadsheets: Comparing traditional Design Control methods to modern eQMS traceability.[11:00] Accelerating Compliance: How Greenlight Guru's QMS Templates dramatically cut implementation time.[13:30] The Bloated QMS: Why adopting procedures from large corporations may hinder small-to-midsize companies.[16:00] Design Quality Explained: Marrying R&D/Product Development with QMS compliance.[21:30] The MedTech Ethos: Focusing on the patient and improving quality of life.[27:00] CAPA Management Insights: The critical distinction between Correction and Corrective Action.[30:25] Navigating the QMSR Transition: Reassurance that compliance isn't "that deep" if you are already ISO 13485 compliant.Quotes"It's a rewarding thing to just understand that you don't need to know everything. I think that's a thing that... people should realize and they should reach out to other people that are smarter or more experienced in realms that they don't understand." - Alex Naber"I think what got me into MedTech was more of the ethos behind it... We're creating products to make patients' lives better, to impact our world, our society in a positive manner, to give a better quality of life to individuals." - Alex NaberTakeawaysSeek a Unified Quality Solution: Fragmented quality processes (e.g., design controls in spreadsheets separate from the QMS) introduce significant regulatory risk. Adopting an eQMS, like the Greenlight Guru QMS solution, creates true traceability and dramatically streamlines compliance.Design Quality as a Partner, Not Police: Design Quality Engineers should actively partner with R&D, not just enforce rules. This involves educating product development teams on the why behind documentation and regulations to collaboratively find compliant solutions.Implement CAPA Early and Correctly: A robust CAPA process is essential long before market entry. Quality professionals must know the difference between a correction (fixing the immediate issue) and a corrective action (addressing the root cause) to prevent systemic non-conformances.Leverage QMS Templates for Speed: For new or growing companies, utilizing pre-validated QMS templates, like those offered by Greenlight Guru, can cut months off the time required to establish a 13485 or FDA CFR Part 820/EU MDR compliant system.QMSR is Not Overwhelming: As the QSR evolves into the Quality Management System Regulation (QMSR), companies already adhering to ISO 13485 will find the transition is relatively minor, primarily requiring minor updates rather than a complete overhaul of their existing QMS.ReferencesAlex Naber's LinkedInEtienne Nichols' LinkedIn: Connect with EtienneISO 13485:2016: The international standard specifying requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer and applicable regulatory requirements. Relevance: This is the foundation for managing QMS changes, including the QMSR transition.Quality Management System Regulation (QMSR): The upcoming modernization of the FDA’s Quality System Regulation (21 CFR Part 820), harmonizing U.S. requirements with ISO 13485. Relevance: The central regulatory change discussed at the end of the episode.MedTech 101 SectionDesign Quality: In the medical device industry, Design Quality (DQ) is a specialized function within the Quality Assurance (QA) department. Its role is to ensure that the process used to design and develop a new medical device is compliant with the company's QMS procedures and applicable regulations (like FDA 21 CFR Part 820 or ISO 13485). Think of Design Quality as the engineer's compass and map for compliance—they guide the R&D team to make sure every requirement, test, and risk mitigation is properly documented and linked, preventing costly issues down the line. Without DQ, R&D teams might build a great product that can't be legally sold.Correction vs. Corrective Action: These two terms are often confused in quality management:Correction: The immediate action taken to fix a non-conforming issue. Example: A batch of surgical instruments has burrs, so the correction is to re-polish them.Corrective Action (CAPA): A deeper, systemic action taken to eliminate the root cause of a non-conformance so it does not happen again. Example: The corrective action is revising the manufacturing work instruction to include mandatory daily calibration of the machine causing the burrs.Feedback Call-to-ActionWe want to be your trusted voice in MedTech! We are committed to providing the most useful, actionable insider knowledge in the industry. Please help us by sharing your thoughts on this episode, suggesting future topics, or leaving a personalized review on your favorite podcast platform.Send your feedback, topic ideas, and questions directly to podcast@greenlight.guru. We personally read every email and truly value your input.SponsorsThis episode of the Global Medical Device Podcast is brought to you by Greenlight Guru, the only MedTech-specific platform that provides both a powerful Quality Management System (QMS) and industry-leading Electronic Data Capture (EDC) solutions. Alex Naber, an expert consultant from Greenlight Guru, highlights in this episode how integrating your design controls—the subject of his design quality expertise—directly into a compliant eQMS is the key to accelerating product development, eliminating audit anxiety, and truly improving the quality of life for patients. To learn more about how Greenlight Guru's dedicated solutions can streamline your path to market, visit www.greenlight.guru.